STORM Therapeutics Limited’s Post

#STORM's Senior Vice President Therapeutics, Matthew Fyfe, is chairing a session at the International Symposium on Medicinal Chemistry next week! Find the session details below if you are attending.   📢 Title: Session 4 'Chemical Biology': Targeting RNA and RNA-Regulatory Proteins 🕐 Date & Time: Monday 2nd September, 13:45 CEST 📍 Rome, Italy   Get in touch to arrange a meeting with the STORM team.   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA #STC15 #EFMC2024 #medicinalchemistry #chemicalbiology

Great to see STORM's CEO, Jerry McMahon, featured in Citeline's discussion on advancements in #oncology and the use of technology in the evolving landscape of drug development. 💡 An insightful discussion where Jerry provided his thoughts amongst industry experts from #ASCO2024!   📰 Check out the clip below or read the report in full here: https://lnkd.in/eJXfzsbK   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA

Great to see #STORMTherapeutics featured in Labiotech.eu's summary of 'Six epigenetics companies making strides in 2024', highlighting STORM's significance as an up-and-coming player in the industry!   Read the article to discover more about STORM's lead candidate #STC15 which is advancing in a Phase 1 study and is the first RNA methyltransferase inhibitor to enter the clinic. Recent interim data presented at American Society of Clinical Oncology (ASCO) Annual Meeting, found that STC-15 was well-tolerated and clinical activity was measured in solid tumors. An 11% overall response rate and 63% disease control rate were observed. https://lnkd.in/enqj5ifA   Thanks to Roohi Mariam Peter for highlighting us!   To learn more about STORM and our first-in-class pipeline targeting #RNA modifying enzymes follow us on LinkedIn!   #lifesciences #biotech #drugdiscovery #research #METTL3 #METTL1 #RNA #ASCO2024 #epigenetics

We are delighted to share that #STORMTherapeutics is featured in the Medical Technology Magazine 'ASCO 2024 unveils practice - changing research in oncology' article. Richard Staines reports on the cutting-edge research presented at ASCO.   STORM's CEO, Jerry McMahon provided insight on current therapies and further advancements made in oncology research, commenting 'Success now is all about big improvements in progression free survival and overall survival.' Read the full article here: https://bit.ly/3WwARjS.

Excited to share that we’ve been featured in Drug Hunter's latest article, “Targeting Post-Transcriptional RNA-Modification with a First-to-Clinic METTL3 Inhibitor: STC15”!   This piece offers an excellent update on #METTL3, sharing the exciting journey of #STC15 and the latest advancements we presented at #ASCO2024.   Thank you to Drug Hunter for following our story. We’re eager to continue making significant strides and sharing our progress with you all!   #ASCO #clinicalresearch #RNA #smallmolecule #innovation #biotech #drugdevelopment #RNA

Not long until #STORM is presenting at #ISMB2024: Intelligent Systems for Molecular Biology by ISCB - International Society for Computational Biology! Hendrik Weisser, Group Leader Bioinformatics at STORM, will be presenting a poster next week at the world's largest conference focused on #bioinformatics and #computationalbiology.   📢 Presentation details: D-326: R toolkit for biomarker discovery, Track: TransMed 📅 Date, time & location: Tuesday 16th July, 12:20-14:20 EDT - Montreal, Canada   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA

#STORM's Senior Vice President Therapeutics, Matthew Fyfe, is joining a panel at #ONHelix2024! 4th July at 15:30 BST   'Translational Research in a Global Village' panelists will reflect on what's driving the UK life science sector's growth as a global bio-innovation location.   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA #OneNucleus #ONHelix

#STORM's Vice President Medicinal Chemistry, Beth Thomas, is presenting at the Society for Medicines Research's 'Modulating RNA with oligonucleotides or small molecules' conference today!   Beth will be presenting from 13.50 - 14.30 BST on the 'Discovery of STC15, the First Molecule Specifically Targeting an RNA Methyltransferase Enzyme to Enter Clinical Development'.   The one-day conference brings together speakers who will explore successful approaches, future opportunities, and novel approaches being explored in industry and academia to exploit ways to downregulate, upregulate or change splicing in protein synthesis for therapeutic purposes.   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA #modification

📢 Join #STORM at the STING & TLR-Targeted Therapies Summit where Yaara Ofir-Rosenfeld, STORM's Director of Translational Oncology, is presenting!   Yaara's presentation, entitled 'Inhibition of METTL3 Activates Innate Immunity Pathways & Reshapes the Tumor Microenvironment' will be taking place at 15:30 PDT on Wednesday 19th June.   The meeting runs from the 19-20th June in San Diego and explores new targets and clinical trials targeting innate immune pathways.   See you there!   #lifesciences #biotech #drugdiscovery #research #STC15 #METTL3 #METTL1 #RNA #modification

Many congratulations to our founder Tony Kouzarides on his Knighthood. What a fantastic achievement and recognition for his work.